title: Bleeding risk factors in chronic oral anticoagulation with acenocoumarol.
abstract: We studied major bleeding complications, death related to hemorrhage, and tried to identify predisposing factors for bleeding in outpatients treated with acenocoumarol. We evaluated 811 outpatients attending a specialized anticoagulant therapy unit. The intended INR range was 3.5-4.5 for mechanical heart valve replacement (N= 384) and 2.0-3.0 for other indications (N= 427). The variability of INR for the total follow-up and the 2 months before the hemorrhage was calculated. The total follow-up was 1,963.26 years with 27,321 control tests. We observed 47 major bleeding episodes, including 2 fatal (central nervous system hemorrhages), in 37 patients. 49.5% of the patients had underlying diseases. The rate of major and fatal hemorrhage was 2.39 and 0.10 episodes per 100 patients year, respectively. Hemorrhagic complications were more frequently observed in patients with a more intense intended range (8.2% in the INR 3.5-4.5 group vs. 1.5% in the 2.0-3.0 INR group). The risk of major bleeding increased in patients with an achieved INR higher than 6 and in those with higher INR variability during follow-up. The estimated probability of bleeding also increased with time: it was 0.102% at 78 months, and at the beginning of therapy it was 0.006% and 0.007% at 1 and 4 months, respectively. The intensity of anticoagulation and the deviation of the INR from the target are the most important risk factors for bleeding in patients taking acenocoumarol. Monitoring the variability of INR can help identifying patients predisposed to bleeding. However, the screening for underlying disease should always be performed.
authors.affiliation: Departamento de Hemostasia y Trombosis, Instituto de Investigaciones Hematológicas "Mariano R. Castex," Academia Nacional de Medicina de Buenos Aires, Argentina.
authors.forename: P
authors.initials: P
authors.lastname: Casais
authors.forename: A
authors.initials: A
authors.lastname: Sánchez Luceros
authors.forename: S
authors.initials: S
authors.lastname: Meschengieser
authors.forename: C
authors.initials: C
authors.lastname: Fondevila
authors.forename: M T
authors.initials: MT
authors.lastname: Santarelli
authors.forename: M A
authors.initials: MA
authors.lastname: Lazzari
mesh_terms: D000074:Acenocoumarol / Q000627:therapeutic use*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006470:Hemorrhage / Q000453:epidemiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000925:Anticoagulants; D000074:Acenocoumarol